Alzamend Neuro

General Information

We are a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. With our two current and future product candidates, we aim to bring treatments or cures to market at a reasonable cost as quickly as possible. Far too many individuals — patients and caregivers — suffer from the burden created by these devastating, and often fatal, diseases. Our primary target, Alzheimer’s disease, was among the most-feared diseases (second only to cancer) among Americans, according to a 2011 survey by the Harvard School of Public Health. Alzheimer’s is also the sixth leading cause of death in the United States according to a 2021 report from the Alzheimer’s Association, a nonprofit that funds research. Existing Alzheimer’s treatments only temporarily relieve symptoms but do not slow or halt the underlying worsening of the disease, which currently affects roughly 6.2 million Americans and that number is expected to grow to 13 million individuals by 2050.

(Note: Alzamend Neuro priced its IPO on June 14, 2021, in line with the terms in its prospectus: 2.5 million shares at $5 each to raise $12.5 million.)

Employees: 4
Founded: 2016
Contact Information
Address 3802 Spectrum Boulevard, Suite 112C Tampa, Florida 33612, US
Phone Number (844) 722-6333
Web Address
View Prospectus: Alzamend Neuro
Financial Information
Market Cap $424.6mil
Revenues $0 mil (last 12 months)
Net Income $-3.8 mil (last 12 months)
IPO Profile
Symbol ALZN
Exchange NASDAQ
Shares (millions): 2.5
Price range $5.00 - $5.00
Est. $ Volume $12.5 mil
Manager / Joint Managers Spartan Capital Securities
CO-Managers --
Expected To Trade: 6/15/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change